SLS 외환 뉴스
SELLAS Says FDA Grants Rare Pediatric Disease Designation For SLS009 To Treat Pediatric ALL
Biopharmaceutical company SELLAS Life Sciences Group, Inc. (SLS) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia (ALL).
RTTNews
|
133 일 전
SELLAS Life Sciences Reports Positive Topline Data In Lymphoma Cohort From SLS009 Phase 1 Trial
SELLAS Life Sciences Group, Inc. (SLS) announced Thursday positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from the Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009).
RTTNews
|
410 일 전
